Latest issue of Clinical laboratory
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Carina Biotech to create cancer-busting CAR-T cells using Bionomics antibody
, /in E-News /by 3wmediaIn an exclusive agreement with Bionomics Limited, Australia’s Carina Biotech will create Chimeric Antigen Receptor T cells (CAR-T cells) and other adoptive cell therapies to the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) using the first-in-class humanised antibody BNC101 developed by Bionomics.
BioMedion buys compliance division of arivis
, /in E-News /by 3wmediaBioMedion, a global Compliance Management Software company providing controlled content and raw data management solutions for the life science industry, has acquired the Compliance Division of arivis, a provider of regulatory software and biomedical 3D and big image data software solutions.
Nordic Capital, Astorg jointly acquire Cytel
, /in E-News /by 3wmediaNordic Capital and Astorg have jointly acquired acquire Cytel Inc. from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution.
LSBio acquires Absolute Antibody
, /in E-News /by 3wmediaSeattle, US-based LSBio, a leading provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody and its sister company Kerafast. Terms of the transaction were not disclosed.
European Commission’s Open Research Europe platform up and running
, /in E-News /by 3wmediaThe new Open Research Europe (ORE) platform – funded by the European Commission – is now up and running.
Ovarian cancer project shows promise
, /in E-News /by 3wmediaDue to promising results, Porvair Sciences has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.
Mogrify secures IP foundational to its cell conversion technology
, /in E-News /by 3wmediaUK-based Mogrify has secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (Mogrify V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (Mogrify V2). The expansion of rights allows the Company to bring the latest version […]
Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test
, /in E-News /by 3wmediaNovigenix SA Switzerland, a pioneer in immuno-transcriptomics for precision medicine, will lead a consortium, including PamGene International and Radboud University (The Netherlands), to develop a blood based multi-omics test to predict response to immune checkpoint inhibitors in cancer. The consortium has been awarded a grant up to €1 million under the Eurostars programme.
Pepscope secures investment to boost development kinase inhibitor therapies
, /in E-News /by 3wmediaDutch biotech company Pepscope, offering endogenous protein kinase activity profiling technologies, has secured €4.3 million funding to further develop and commercialize their lead product QuantaKinome.
RetinAI to provide AI solutions for Novartis ophthalmology research
, /in E-News /by 3wmediaSwitzerland-based RetinAI Medical will collaborate with Novartis Pharma in a multi-year agreement which will see RetinAI’s artificial intelligence tools employed to support multiple projects in ophthalmology. Both companies have previously worked successfully on pilot projects in this disease area.